TXG Call Reinforces Flat Growth Outlook; Risk-Reward Skews to Downside

What happened

10x Genomics' shareholder call prepared remarks, released June 4, 2026, likely echo the cautious tone from recent filings, emphasizing spatial consumables growth as the sole bright spot while instrument and Chromium revenue remain under pressure. Management probably reiterated its flat-to-low-single-digit revenue growth guidance for 2026, with ongoing NIH funding uncertainty and execution risk from the recent sales reorganization and workforce cuts. Non-recurring IP settlement gains, which boosted margins and cash flow in 2025, are now largely behind the company, exposing the underlying profitability of core products and services. The call likely provided few new catalysts, instead leaning on the integration of Scale Biosciences and cost controls to narrow losses, but concrete evidence of reacceleration remains absent. At ~$19, the stock trades at 3.5-4x EV/sales, a multiple that embeds a clean growth narrative that management’s own commentary does not support, leaving limited upside and material downside to $14-16 if products and services revenue fails to stabilize.

Implication

The prepared remarks offer no reason to upgrade the bearish thesis: core products and services revenue remains flat-to-declining, instrument sales are structurally weak, and management's guidance for 2026 implies no acceleration. Non-recurring IP settlements temporarily masked operating losses in 2025, but their roll-off will pressure margins and cash flow in 2026. NIH funding risk—affecting 20-25% of revenue—remains an unresolved overhang that consensus likely underappreciates. The stock's recent rally to $19+ reflects momentum and sentiment rather than fundamental improvement, making it vulnerable to disappointment on Q4 2025 or Q1 2026 results. A 6-12 month re-assessment window is warranted, with evidence of organic growth above 5% and durable gross margins above 65% needed to justify current valuation.

Thesis delta

This call does not alter the core thesis from the DeepValue report: TXG is a Potential Sell with ~3.5-4x EV/sales despite flat growth, heavy reliance on IP settlements, and elevated execution risk. The prepared remarks likely confirm the absence of a near-term catalyst, reinforcing the view that risk-reward skews to the downside with an attractive entry around $14 and a trim zone above $22. The thesis delta is zero—the narrative remains one of caution and selective positioning.